Search results for "survival analysi"

showing 10 items of 752 documents

Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study

2021

Background: The aim of the present study was to assess the prognostic value of tumour-free distance (TFD), defined as the minimum distance of uninvolved stroma between the tumour and peri-cervical stromal ring, in early-stage cervical cancer. Methods: Patients with pathologic FIGO 2009 stage IA1–IIA2 cervical cancer, treated by primary radical surgical treatment between 01/2000 and 11/2019, were retrospectively included. Adjuvant treatment was administered according to the presence of previously established pathologic risk factors. TFD was measured histologically on the hysterectomy specimen. Pre-operative TFD measured at MRI-scan from a cohort of patients was reviewed and compared with pat…

AdultOncologyCancer Researchmedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentUterine Cervical NeoplasmsHysterectomyArticlesurgery03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicinelocally advanced cervical cancerHumansMedicineStage (cooking)AgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancer...Hysterectomybusiness.industrylocally advanced cervical cancer surgeryMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisSettore MED/40 - GINECOLOGIA E OSTETRICIATreatment OutcomeOncologyLymphatic Metastasis Magnetic Resonance ImagingLymphatic Metastasis030220 oncology & carcinogenesisCohortRadiographic Image Interpretation Computer-AssistedFemaleLymphbusinessCohort studyBritish Journal of Cancer
researchProduct

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

2006

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …

AdultOncologyTRIAL COMPARING CISPLATINmedicine.medical_specialtysecond-line therapy PLATINUM-BASED CHEMOTHERAPYOrganoplatinum CompoundsCyclophosphamidemedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaPACLITAXELchemotherapyGastroenterologySINGLE-AGENTPolyethylene GlycolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineEVALUATETOPOTECANCOMBINATIONCyclophosphamideAgedOvarian NeoplasmsChemotherapybusiness.industrySALVAGE CHEMOTHERAPYoxaliplatinObstetrics and GynecologyCombination chemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisCANCEROxaliplatinRegimenliposomal doxorubicinovarian cancerOncologyDoxorubicinFemaleNeoplasm Recurrence LocalbusinessOvarian cancerFOLLOW-UPmedicine.drug
researchProduct

Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?-A retrospect…

2016

The Z0011 trial has fundamentally changed axillary management in breast cancer patients. However, some important questions remain, like the role of extracapsular nodal extension (ENE) in positive sentinel nodes and the need for further axillary treatment. In this retrospective cohort study, we reviewed and analyzed data from 342 clinically node negative (cN0) breast cancer patients with a positive sentinel node and subsequent axillary lymph node dissection (ALND) from the BRENDA data base. The 104 (30.4%) ENE positive patients had a significantly higher proportion of ≥3 positive axillary lymph nodes (65.0%) compared to ENE negative patients with a positive sentinel node (21.4%). Likewise, E…

AdultOncologymedicine.medical_specialtyAxillary lymph nodesBreast NeoplasmsMetastasis03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineLymph nodeAgedRetrospective StudiesAged 80 and overUnivariate analysisSentinel Lymph Node Biopsybusiness.industryAxillary Lymph Node DissectionRetrospective cohort studyMiddle AgedSentinel nodemedicine.diseaseSurvival Analysismedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisFemaleSurgerySentinel Lymph NodebusinessThe Breast Journal
researchProduct

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by E…

2011

Background: The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel (Taxotere, D) followed by four cycles of EC as adjuvant treatment of node-positive breast cancer. Patients and methods: Patients were randomly assigned to EC (E 120 mg/m 2 , C 600 mg/m 2 , arm A) for four cycles or four cycles of D (100 mg/m 2 ) followed by four cycles of EC (arm B), both regimens every 21 days. Hormone receptor-positive patients were given hormonal therapy for 5 years. Primary end point was 5-year disease-free survival (DFS). Secondary objectives were overall survival (OS) and safety. Results: There were 750 p…

AdultOncologymedicine.medical_specialtyCyclophosphamideBreast NeoplasmsDocetaxelDisease-Free SurvivalBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideSurvival analysisEpirubicinGynecologyDose-Response Relationship Drugbusiness.industryCarcinomaHazard ratioOriginal ArticlesHematologyMiddle Agedmedicine.diseaseSurvival AnalysisItalyOncologyDocetaxelLymphatic MetastasisHormonal therapyFemaleTaxoidsLymph NodesbusinessAlgorithmsmedicine.drugEpirubicinAnnals of Oncology
researchProduct

Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients: 10 years experience at the Departmen…

2003

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. chi2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor s…

AdultOncologymedicine.medical_specialtyMultivariate analysisAdenocarcinomaMedical RecordsCarcinoma AdenosquamousObstetrics and gynaecologyGermanyInternal medicineDiabetes MellitusCarcinomaHumansMedicineNeoplasm InvasivenessStage (cooking)Survival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetaplasiaUnivariate analysisbusiness.industryProportional hazards modelObstetrics and GynecologyMiddle AgedProgesterone Receptor StatusPrognosismedicine.diseaseSurvival AnalysisEndometrial NeoplasmsOncologyLymphatic MetastasisMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessInternational Journal of Gynecological Cancer
researchProduct

Survival and prognostic factors in patients with oral squamous cell carcinoma

2020

Background This study aimed to evaluate sociodemographic and clinical factors influencing overall survival (OS) in patients with oral squamous cell carcinoma (OSCC). Material and Methods Medical charts of 547 patients with OSCC from a public hospital in northeastern Brazil seen between 1999 and 2013 were evaluated. Survival analysis was performed using the Kaplan-Meier method. The influence of age, sex, ethnicity, clinical stage, anatomical location, type of treatment, and comorbidities on the patients’ prognosis was evaluated. Cox proportional hazards regression model was used to identify independent prognostic factors. Results The 5-year OS was 39%. Multivariate analysis showed that age <…

AdultOncologymedicine.medical_specialtyPoor prognosisYounger ageMultivariate analysisneoplasmsglandular and epithelial03 medical and health scienceshead and neck neoplasms0302 clinical medicineOral Cancer and Potentially malignant disordersInternal medicinefollow up studiesCox proportional hazards regressionHumansMedicineBasal cellIn patientStage (cooking)General DentistryUNESCO:CIENCIAS MÉDICASSurvival analysisRetrospective StudiesSquamous Cell Carcinoma of Head and Neckbusiness.industryResearchrare diseases030206 dentistryPrognosisstomatognathic diseasesOtorhinolaryngologyCarcinoma Squamous CellMouth NeoplasmsepidemiologySurgerybusinessBrazilMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Effect of cost on early removal of contraceptive implants: a prospective cohort study

2019

OBJECTIVES To evaluate the effect of the cost of subdermal etonogestrel implant (SEI) on the continuation rate one year after insertion, and to assess the reasons given by users to remove the implant before the expiration date. METHODS Prospective cohort study conducted among 265 women who chose the SEI as a contraceptive method in a sexual and reproductive health center in the eastern region of Spain, between October/2012 and October/2017. The sample was divided into two cohorts depending on the cost of the implant for the user (free-of-charge or requiring partial payment). Kaplan-Meier survival curves were used to compare the cumulative removal rates of free implants with partially paid i…

AdultTime FactorsDentistry03 medical and health sciences0302 clinical medicineHumansMedicinePharmacology (medical)Prospective Studies030212 general & internal medicineProspective cohort studyDevice RemovalSurvival analysisReproductive health030219 obstetrics & reproductive medicineProportional hazards modelbusiness.industryConfoundingObstetrics and GynecologyContraceptionReproductive MedicineSpainCosts and Cost AnalysisFemaleImplantContraceptive implantbusinessUnintended pregnancyIntrauterine DevicesThe European Journal of Contraception &amp; Reproductive Health Care
researchProduct

Vaginal-assisted laparoscopic radical hysterectomy: rationale, technique, results.

2012

The authors conclude that vaginal-assisted laparoscopic radical hysterectomy is an oncologic viable alternative to abdominal radical hysterectomy, laparoscopic-assisted radical vaginal hysterectomy, totally laparoscopic radical hysterectomy, and robotic radical hysterectomy.

AdultUterine Cervical Neoplasmmedicine.medical_specialtymedicine.medical_treatmentUterine Cervical NeoplasmsUrologic complicationPostoperative ComplicationsUrologic complicationsmedicineHysterectomy VaginalScientific PapersHumansRadical hysterectomyEndometrial NeoplasmRadical HysterectomyStage (cooking)Survival analysisAgedNeoplasm StagingCervical cancerAged 80 and overHysterectomybusiness.industryPostoperative complicationMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurvival AnalysisSurgeryEndometrial NeoplasmsLaparoscopic radical hysterectomymedicine.anatomical_structureTreatment OutcomeVaginaCervical cancerSurgeryFemaleLaparoscopyPostoperative ComplicationSurvival AnalysiCervical cancer; Laparoscopic radical hysterectomy; Urologic complicationsNeoplasm GradingLaparoscopic radical hysterectomybusinessHumanJSLS : Journal of the Society of Laparoendoscopic Surgeons
researchProduct

Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival

1999

Since detailed knowledge regarding the pathophysiological properties—which in turn are responsible for differences in contrast enhancement—remain fairly undetermined, it was the aim of this study (i) to examine the association of standard and pharmacokinetic analysis of time-intensity curves in dynamic MRI with histomorphological markers of tumor angiogenesis (microvessel density [MVD]; vascular endothelial growth factor [VEGF]) and (ii) to determine the ultimate value of a histomorphological and a dynamic MRI approach by correlation of those data with disease outcome in patients with primary cancer of the uterine cervix. Pharmacokinetic parameters (amplitude A, exchange rate constantk 21) …

AdultVascular Endothelial Growth Factor APathologymedicine.medical_specialtyTime FactorsBiophysicsUterine Cervical NeoplasmsEndothelial Growth Factorschemistry.chemical_compoundText miningPharmacokineticsBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingSurvival analysisCervical cancerLymphokinesNeovascularization PathologicRadiological and Ultrasound TechnologyVascular Endothelial Growth Factorsbusiness.industryMicrocirculationGold standard (test)Middle Agedmedicine.diseaseMagnetic Resonance ImagingPathophysiologySurvival RateVascular endothelial growth factorchemistryDynamic contrast-enhanced MRIFemaleNuclear medicinebusinessMagnetic Resonance Materials in Physics, Biology and Medicine
researchProduct